Market Snapshot: Gram-Negative Antibiotics Progress As Urgency Grows

Several antibiotics have moved into late-stage development to treat resistant gram-negative infections, with drug makers banking that the urgent need for new drugs will pave the way for swift regulatory reviews and premium pricing.